Try our mobile app

Published: 2024-02-02 00:00:00 ET
<<<  go to ABBV company page
abbv-20240202
0001551152false00015511522024-02-022024-02-020001551152exch:XCHIus-gaap:CommonStockMember2024-02-022024-02-020001551152exch:XNYSus-gaap:CommonStockMember2024-02-022024-02-020001551152abbv:Sec1.375SeniorNotesDue2024Memberexch:XNYS2024-02-022024-02-020001551152exch:XNYSabbv:Sec1250SeniorNotesDue2024Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec1250SeniorNotesDue2031Member2024-02-022024-02-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _____________________________________________________
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 2, 2024
 
ABBVIE INC.
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation)   Identification No.)
 _____________________________________________________
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
 
Registrant’s telephone number, including area code:  (847) 932-7900
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐                      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐                      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐                      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐                      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 Par Value ABBV New York Stock Exchange
Chicago Stock Exchange
1.375% Senior Notes due 2024ABBV24New York Stock Exchange
1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange
0.750% Senior Notes due 2027ABBV27New York Stock Exchange
2.125% Senior Notes due 2028ABBV28New York Stock Exchange
2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange
2.125% Senior Notes due 2029ABBV29New York Stock Exchange
1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐  


Item 2.02.  Results of Operations and Financial Condition
 
On February 2, 2024, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023.  A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
 
Item 9.01 Financial Statements and Exhibits

(d) Exhibits
Exhibit No. Exhibit
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).



SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
ABBVIE INC.
Date:February 2, 2024By:/s/ Scott T. Reents
Scott T. Reents
Executive Vice President,
Chief Financial Officer